Table 1.
Associations between GPR81 expression and clinicopathological characteristics of human breast cancer specimens (n = 145).
| Features | Total no | Sample no | GPR81 expression | |
|---|---|---|---|---|
| Negative, n (%) | Positive, n (%) | |||
| TNM | 30 | |||
| T2N0M0 | 17 | 1 (5.9) | 11 (94.1) | |
| T2N1M0 | 6 | 1 (16.7) | 5 (83.3) | |
| T2N2M0 | 3 | 0 (0) | 3 (100) | |
| T3N0M0 | 1 | 0 (0) | 1 (100) | |
| T3N1M0 | 2 | 0 (0) | 2 (100) | |
| T4N2M0 | 1 | 1 (100) | 0 (0) | |
| TNM stage | 30 | |||
| Stage I | 0 | 0 (0) | 0 (0) | |
| Stage II | 24 | 2 (8.3) | 22 (91.7) | |
| Stage III | 6 | 1 (16.7) | 5 (83.3) | |
| Stage IV | 0 | 0 (0) | 0 (0) | |
GPR81 G-protein-coupled receptor 81, TNM tumor‑node‑metastasis.